4127.TWO Tien Liang BioTech Co., Ltd.
- Market cap
- TWD 1.51B
- P/E
- 21.7x
- P/B
- 3.06x
- ROE
- 18.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4127.TWO undervalued?
Graham number4127.TWO trades 71.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tien Liang BioTech Co., Ltd. fundamental analysis
No fundamental analysis for Tien Liang BioTech Co., Ltd. yet.
Tien Liang BioTech Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese and Western medicine, other healthcare, and cosmetic products through online and offline channels. Tien Liang BioTech Co., Ltd. was founded in 1971 and is based in New Taipei City, Taiwan.
Full company profileTien Liang BioTech Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tien Liang BioTech Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 436M | 431M | 571M | 529M | 460M | 385M | 512M | 766M |
| Gross Profit | 242M | 252M | 338M | 337M | 286M | 230M | 288M | 461M |
| Operating Income | -43.4M | -46.6M | 50.6M | 61.1M | 20.4M | 593K | -16.1M | 55.0M |
| EBITDA | -21.6M | -31.8M | 63.1M | 72.1M | 31.0M | 25.5M | 9.45M | 119M |
| Net Income | -46.8M | -51.6M | 46.6M | 59.5M | 17.7M | 11.7M | -10.3M | 96.7M |
| EPS | -1.02 | -1.13 | 1.02 | 1.30 | 0.39 | 0.25 | -0.22 | 2.11 |
| Balance Sheet | ||||||||
| Total Assets | - | 625M | 655M | 676M | 654M | 889M | 1.18B | 1.22B |
| Total Liabilities | - | 258M | 241M | 201M | 161M | 411M | 709M | 704M |
| Shareholders' Equity | - | 367M | 414M | 475M | 493M | 478M | 474M | 519M |
| Cash & Short-term Investments | 55.7M | 115M | 118M | 108M | 142M | 131M | 122M | 167M |
| Total Debt | - | 184M | 157M | 114M | 84.7M | 345M | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | - | -10.8M | 45.2M | 21.9M | 69.7M | 48.3M | 19.2M | 94.5M |
| Capital Expenditure | 0.00 | 1.49M | 597K | 1.01M | 5.34M | 4.14M | 23.3M | 21.6M |
| Free Cash Flow | - | -12.3M | 44.6M | 20.9M | 64.3M | 44.2M | -4.10M | 72.9M |
| Ratios | ||||||||
| ROE | - | -14.1% | 11.3% | 12.5% | 3.6% | 2.4% | -2.2% | 18.6% |
| ROA | - | -8.3% | 7.1% | 8.8% | 2.7% | 1.3% | -0.9% | 7.9% |
| Net Profit Margin | -10.7% | -12.0% | 8.2% | 11.3% | 3.9% | 3.0% | -2.0% | 12.6% |
| Debt to Equity | - | 0.50x | 0.38x | 0.24x | 0.17x | 0.72x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tien Liang BioTech Co., Ltd. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 27, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 22.9M | 0.49 | 195.6% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 104:100 on Sep 24, 2008.
Who owns Tien Liang BioTech Co., Ltd.
- Insiders 64.01%
- Institutions 0.00%
- Public & others 35.99%
- Shares outstanding 45.8M
- Free float 2.00M
Tien Liang BioTech Co., Ltd. company profile
- Company name
- Tien Liang BioTech Co., Ltd.
- Ticker
- 4127.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 88
- Fiscal year end
- December
- Address
- No. 147, Datong Road, New Taipei City, Taiwan
- Phone
- 886 2 2648 3099
- Website
- tlb.com.tw
About Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese and Western medicine, other healthcare, and cosmetic products through online and offline channels. Tien Liang BioTech Co., Ltd. was founded in 1971 and is based in New Taipei City, Taiwan.
Tien Liang BioTech Co., Ltd. management
1- Junxiong GuoFinance Manager & Accounting Supervisor